- Associate Professor, Faculty of Pharmacy, Université de Montréal
- Co-Director, Montreal Cancer Consortium
- Co-Holder, Jean-Guy Sabourin Chair
- Researcher at the CRCHUM
- Research member at the Montreal Cancer Institute
My laboratory has identified the CD73 enzyme, which generates extracellular adenosine, as a novel therapeutic target in immuno-oncology. We are studying the role of the adenosinergic pathway in oncology. We also study the mechanisms of resistance to anti-PD-1/L1 therapies.
- Bertrand Allard, Ph.D., research associate
- Sandra Pommey, M.Sc., research associate
- Isabelle Cousineau, Ph.D., research assistant
- Yacine Bareche, Ph.D., postdoctoral fellow
- David Allard, Ph.D. Student
- Chloé Thivierge, animal health technician
Email Address for application
Dr. Stagg received his PhD from McGill University and pursued postdoctoral training in immuno-oncology in Melbourne, Australia from 2005 to 2010. Dr. Stagg’s work has identified the CD73-adenosine axis as a novel therapeutic target in immuno-oncology, leading to the development of targeted therapies currently in clinical trials. Dr. Stagg is a Canadian Institutes of Health Research Scholar and co-holder of the Jean-Guy Sabourin Pharmaceutical Chair in Women’s Health at the Université de Montréal.